Treatment of hypoparathyroidism

Francesco Tecilazich, Anna Maria Formenti, Stefano Frara, Raffaele Giubbini, Andrea Giustina

Research output: Contribution to journalReview articlepeer-review


The goal of the clinical management of hypoparathyroidism is to correct acute and chronic hypocalcemia. Treatment of acute hypoparathyroidism via intravenous infusion of Ca++ salts, is necessary only in symptomatic patients, or in asymptomatic patients in the setting of a rapid decrease in ionized Ca++ levels. The treatment cornerstones of chronic hypoparathyroidism are oral supplementation of calcium and/or active vitamin D, that can be associated with dietary restriction of sodium and phosphates, thiazide diuretics, and phosphate binders. Notably, PTH replacement is emerging as a innovative treatment of chronic hypoparathyroidism. rhPTH (1-84) has been shown to safely reduce calcium and vitamin D dosage, and increase serum calcium levels in hypoparathyroid patients. Therefore, rhPTH (1-84) appears to represent a new option in patients with chronic hypoparathyroidism "resistant" to conventional treatment.

Original languageEnglish
Pages (from-to)955-964
JournalBest Practice and Research in Clinical Endocrinology and Metabolism
Issue number6
Early online dateDec 6 2018
Publication statusPublished - 2018


Dive into the research topics of 'Treatment of hypoparathyroidism'. Together they form a unique fingerprint.

Cite this